A Phase 2/3 interventional study of Brexpiprazole and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 2/3, and was the 19th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 740 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 14th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2018, is the only one in phase 2/3, and was the 33rd registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IMP administration. For birth control, 2 of the following methods must be used:
vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.
Patients with a diagnosis of any of the following diseases according to
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
Drug: Brexpiprazole
Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
Drug: Brexpiprazole
Tablets, Oral, once daily, 14 weeks
Drug: Placebo
Tablets, Oral, once daily, 14 weeks
Also known as: REXULTI
Tablets, Oral, once daily, 14 weeks
Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B).
The MADRS was a clinician-rated scale which evaluated the level of depression. The MADRS consisted of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item was scored from 0 to 6, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 60, with higher scores indicating worse condition.The mean changes were compared between antidepressant treatments and brexpiprazole as adjunctive therapy.
Time frame: Baseline (the end of Phase A), at completion of administration (Week 6).
CGI-I Improvement Rate at Week 6 of the Double-blind Period (Phase B)
Clinical Global Impression - Improvement (CGI-I) improvement rate: the proportion of participants who score 1 or 2 on the CGI-I scale at Week 6 of the double-blind period (Phase B). The CGI-I Scale was a clinician-rated scale which assessed the total improvement of the participant's condition compared to that at baseline. Scores range from 0 to 7:0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicated worse condition.
Time frame: Baseline (the end of Phase A), at completion of administration (Week 6).
This trial was conducted in 740 participants from 145 trial sites in Japan.
| Milestone | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Started | 250 | 246 | 244 |
| Completed | 238 | 219 | 232 |
| Not completed | 12 | 27 | 12 |
| Withdrew: Adverse event | 3 | 18 | 3 |
| Withdrew: Physician decision | 1 | 0 | 2 |
| Withdrew: Protocol violation | 3 | 8 | 5 |
| Withdrew: Withdrawal by subject | 5 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
The MADRS was a clinician-rated scale which evaluated the level of depression. The MADRS consisted of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item was scored from 0 to 6, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 60, with higher scores indicating worse condition.The mean changes were compared between antidepressant treatments and brexpiprazole as adjunctive therapy.
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B). | -8.5 ± 0.47 | -8.2 ± 0.47 | -6.7 ± 0.47 |
Clinical Global Impression - Improvement (CGI-I) improvement rate: the proportion of participants who score 1 or 2 on the CGI-I scale at Week 6 of the double-blind period (Phase B). The CGI-I Scale was a clinician-rated scale which assessed the total improvement of the participant's condition compared to that at baseline. Scores range from 0 to 7:0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicated worse condition.
| percentage of participants | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| CGI-I Improvement Rate at Week 6 of the Double-blind Period (Phase B) | 35.1 | 35.1 | 29.6 |
Collected over Adverse events were monitored from signing of the informed consent form until post-treatment observation period for up to 30 days (±5 days) after the final day of study medication administration (end of trial date [final day of observation]).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 1 mg | 0/250 (0%) | 3/250 (1.2%) | 108/250 (43.2%) |
| Brexpiprazole 2 mg | 0/246 (0%) | 3/246 (1.2%) | 153/246 (62.2%) |
| Placebo | 0/244 (0%) | 2/244 (0.8%) | 92/244 (37.7%) |
| Event | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| CellulitisInfections and infestations | 0/250 | 0/246 | 1/244 |
| Subarachnoid haemorrhageNervous system disorders | 0/250 | 0/246 | 1/244 |
| Alcoholic pancreatitisGastrointestinal disorders | 0/250 | 1/246 | 0/244 |
| Extramammary Paget's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/250 | 1/246 | 0/244 |
| EpilepsyNervous system disorders | 0/250 | 1/246 | 0/244 |
| AppendicitisInfections and infestations | 1/250 | 0/246 | 0/244 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/250 | 0/246 | 0/244 |
| IIIrd nerve paralysisNervous system disorders | 1/250 | 0/246 | 0/244 |
| Event | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo |
|---|---|---|---|
| AkathisiaNervous system disorders | 15/250 | 60/246 | 3/244 |
| NasopharyngitisInfections and infestations | 20/250 | 16/246 | 24/244 |
| Weight increasedInvestigations | 18/250 | 19/246 | 6/244 |
| TremorNervous system disorders | 16/250 | 12/246 | 9/244 |
| Blood prolactin increasedInvestigations | 6/250 | 15/246 | 6/244 |
| HyperprolactinaemiaEndocrine disorders | 3/250 | 13/246 | 3/244 |
| InsomniaPsychiatric disorders | 9/250 | 12/246 | 8/244 |
| HeadacheNervous system disorders | 6/250 | 3/246 | 11/244 |
| Extrapyramidal disorderNervous system disorders | 1/250 | 11/246 | 2/244 |
| ConstipationGastrointestinal disorders | 5/250 | 9/246 | 5/244 |
Full Analysis Set (FAS) which comprised subjects who, after randomization, had received at least 1 dose of the study medication in the double-blind period (Phase B), and from whose the Montgomery Åsberg Depression Rating Scale (MADRS) total scores had been obtained at baseline and at least 1 time point after initiation of the treatment.
| Age, Categorical(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 248 | 245 | 243 | 736 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 40.9 ± 10.8 | 40.0 ± 10.7 | 39.8 ± 10.8 | 40.2 ± 10.8 |
| Sex: Female, Male(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 116 | 102 | 105 | 323 |
| Male | 132 | 143 | 138 | 413 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Asian | 248 | 245 | 243 | 736 |
| Region of Enrollment(participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 248 | 245 | 243 | 736 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Jul 2018 to primary completion in Jun 2022, 46 months.
Results were first posted in Aug 2024, 2 years 2 months after primary completion.
Of 16 phase 2/3 interventional studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Co., Ltd. →